Back to Agenda
Session 4: Patient Involvement in RWE Development and Integrated Evidence Generation
Session Chair(s)
Michael Lees, MA
Chief Operating Officer and Head of Market Access Strategy
PHMR Ltd, United Kingdom
The involvement of patients in the design, analysis and interpretation of clinical research is increasing, leading to improvements in the design and execution of research as well as the use of the resulting data. While much of the focus is on patient involvement in clinical trials, the design, execution and interpretation of real world research is also improved by the active involvement of patients, as is the potential to integrate clinical and real world research. This session will explore optimal patient involvement in real world research while addressing issues such as the end uses of data and issues of data ownership from the perspective of leading patient advocates, the pharmaceutical industry and from HTA decision makers. A panel discussion in conclusion will give a chance for the development of a call to action to further improve the role of patients in real world research in future.
Speaker(s)
Patient Involvement in Integrated Evidence Generation: What, When, How?
Bettina Ryll
MPNE, Vision Zero Cancer, Sweden
Member of the First EU Cancer Mission Board
How Patient Involvement Improves Evidence Quality: A Pharmaceutical Industry Perspective
Jessica S. Scott, JD, MD
Legacy Health Strategies , United States
President
HTA Decisions and Patient Driven Evidence
Anja Schiel, PhD
Norwegian Medicines Agency (NoMA), Norway
Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA
Have an account?